Evidence map›Paper›PMID 37712272›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2023

[Curcumin suppresses proliferation, migration and invasion of papillary thyriod cancer B-CPAP cells through the Keap1-Nrf2 pathway].

L Ren, M Zou, X Zhu, W Xu, G Liu, J Sun, F Fan, C Zhang

Abstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Bioinformatic analysis of CCND2 expression in papillary thyroid carcinoma and its impact on immune infiltration].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

L RenSchool of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China.
M ZouSchool of Clinical Medicine, Bengbu Medical College, Bengbu 233030, China.
X ZhuSchool of Clinical Medicine, Bengbu Medical College, Bengbu 233030, China.
W XuSchool of Clinical Medicine, Bengbu Medical College, Bengbu 233030, China.
G LiuSchool of Clinical Medicine, Bengbu Medical College, Bengbu 233030, China.
J SunSchool of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China.
F FanSchool of Pharmacy/Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu Medical College, Bengbu 233030, China.
C ZhangDepartment of Anesthesia, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo observe the effects of curcumin on migration and invasion of papillary thyriod cancer B-CPAP cells.

methodsB-CPAP cells were treated with 5, 10, 15, or 20 μmol/L curcumin, and the changes in cell survival, migration and invasion were examined using MTT assay and Transwell assay. ROS levels in the treated cells were detected with a DCFH-DA probe. The expression levels of Nrf2 and Keap1 in the cells were determined using Western blotting and qRT-PCR.

resultsTreatment with curcumin dose- and time-dependently suppressed the viability of B-CPAP cells (

conclusionCurcumin inhibits the proliferation, migration and invasion of papillary thyriod cancer B-CPAP cells probably via the Keap1-Nrf2 signaling pathway.

Indexed as

CurcuminNeoplasmsCell ProliferationHumansKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Reactive Oxygen SpeciesCurcuminKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Reactive Oxygen SpeciesB-CPAPcurcuminKeap1-Nrf2 pathwaypapillary thyriod cancer

Identifiers

PMID37712272
PMCPMC10505584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.